Oruka Upsizes ATM to $500M and Files $1B Universal Shelf
ORKA has more than doubled off its 52-week low of $14.1.
Summary
Oruka Therapeutics upsized its ATM program to $500 million and filed a $1 billion universal shelf, giving it flexibility to raise capital but creating potential dilution for existing shareholders.
Key Events · Financing and Capital Events · ORKA
-
ATM Capacity Increased to $500M
Amendment No. 1 to the Sales Agreement with TD Cowen increases the ATM offering capacity from $200 million to $500 million.
-
$1B Universal Shelf Filed
The new S-3 registers $1 billion in securities, including $365 million in new securities and $635 million carried forward from prior shelves.
-
Illustrative Dilution of $80.57/Share
At an assumed offering price of $104.86, new investors would face immediate dilution of $80.57 per share based on net tangible book value.
-
Overhang on Stock
The increased ATM capacity and shelf registration create a significant potential supply overhang, especially after Fairmount Funds sold $300 million in July.
Analysis · ORKA · Life Sciences
A new S-3 registration statement from Oruka Therapeutics boosts its at-the-market (ATM) offering capacity with TD Cowen from $200 million to $500 million and registers a total of $1 billion in securities. The ATM prospectus assumes a sale price of $104.86 per share, which would dilute new investors by $80.57 per share based on the company's net tangible book value. This filing provides the company with significant additional capital-raising flexibility, but it also creates a substantial overhang on the stock, especially given recent insider selling by Fairmount Funds.
At the time of this filing, ORKA was trading at $107.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $14.10 to $115.52. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.